

31 January 2023

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Total Voting Rights

Cizzle Biotechnology, the UK based diagnostics developer, makes the following announcement in accordance with Rule 5.6.1 of the Financial Conduct Authority's ("FCA") Disclosure Guidance and Transparency Rules.

As of 31 January 2023, the Company's issued ordinary share capital consists of 347,175,106 ordinary shares of 0.01 pence each, each with one voting right. The Company holds no ordinary shares in Treasury. Therefore, the Company's total number of ordinary shares and voting rights is 347,175,106 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Cizzle Biotechnology Holdings plc

Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited

John Depasquale

George Payne

+44(0) 20 33285656

Novum Securities Limited

Colin Rowbury

Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited

Tim Metcalfe

Florence Chandler

+44(0) 20 3934 6630

cizzle@investor-focus.co.uk

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is a spin-out from the University of York that is developing a blood test for the early detection of lung cancer. Its proof-of-concept prototype test is based on the work of Professor Coverley and colleagues to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.